EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：79

作者：

Ke, E-E ^{[1
,2
]}

Wu, Yi-Long ^{[1
,2
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期

关键词：

GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;

D O I：

10.1016/j.tips.2016.09.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.

引用

页码：887 / 903

页数：17

共 50 条

[21] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
Syrigos, Konstantinos
Kotteas, Ilias
Paraskeva, Maria
Gkiozos, Ioannis
Boura, Paraskevi
Tsagouli, Sofia
Grapsa, Dimitra
Charpidou, Andriani
EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[22] What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer
Liu, Si-Yang
Zhang, Jia-Tao
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 217 - +
[23] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
Zhang, Shi-Ling
Zhang, Chan -Yuan
Chen, Yu-Qing
Li, Yu -Fa
Xie, Zhi
Zhang, Xu-Chao
Zhou, Qing
Zhong, Wen-Zhao
Huang, Jie
Sun, Hao
Zheng, Ming-Ying
Xiao, Fa-Man
Yan, Hong-Hong
Lu, Dan-Xia
Lv, Zhi-Yi
Wu, Yi-Long
Chen, Hua-Jun
Yang, Jin-Ji
JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635
[24] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Zhu, Viola W.
Klempner, Samuel J.
Ou, Sai-Hong Ignatius
TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
[25] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, Kyoko
Hata, Akito
Takeshita, Jumpei
Okuda, Chiyuki
Kaji, Reiko
Masago, Katsuhiro
Fujita, Shiro
Katakami, Nobuyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
[26] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Kyoko Otsuka
Akito Hata
Jumpei Takeshita
Chiyuki Okuda
Reiko Kaji
Katsuhiro Masago
Shiro Fujita
Nobuyuki Katakami
Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
[27] FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer
Gold, Kathryn A.
Erasmus, Jeremy J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1131 - 1132
[28] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
Zhang, Hongye
Wang, Ruiyu
Wang, Mingxia
Luo, Judong
Liu, Changmin
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
[29] Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
Wang, Haiyang
Yu, Xiaoqing
Fan, Yun
Jiang, Youhua
ONCOTARGETS AND THERAPY, 2018, 11 : 2149 - 2155
[30] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
Digumarthy, Subba R.
Mendoza, Dexter P.
Padole, Atul
Chen, Tianqi
Peterson, P. Gabriel
Piotrowska, Zofia
Sequist, Lecia, V
CANCERS, 2019, 11 (09)

← 1 2 3 4 5 →